Skip to main content
Premium Trial:

Request an Annual Quote

Two Blades Licenses Genome Engineering Technology to Monsanto for Plant Applications

NEW YORK (GenomeWeb News) – The Two Blades Foundation said on Monday that it has licensed the TAL Code technology to Monsanto on a non-exclusive basis.

Two Blades has exclusive rights for commercial use of the technology in plants. Improvements made to the technology by Monsanto will be used by the foundation as part of its efforts to support subsistence farming.

The technology, discovered by researchers at Martin-Luther University in Halle, Germany, is based on novel sequence-specific DNA binding proteins that can be designed to recognize almost any sequence of interest. Applied to plants, the technology can accelerate improvements in crop growth and development, Two Blades said.

"Having Monsanto, the worlds' largest seed company, put the TAL Code technology to use in their programs will further ensure its wide use and development," Two Blades' Chief Operating Officer Diana Horvath, said in a statement.

Financial and other terms of the deal were not disclosed.

Two Blades is based in Evanston, Ill., and supports the development of durable disease resistance in crop plants.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.